Brief: Zevra Therapeutics Announces Interim Data From The Phase 2 Clinical Trial Of Kp1077 For Idiopathic Hypersomnia
02/10/2023 13:28
Oct 2 (Reuters) - Zevra Therapeutics Inc ZVRA.O :
* ZEVRA THERAPEUTICS ANNOUNCES INTERIM DATA FROM THE PHASE 2
CLINICAL TRIAL OF KP1077 FOR IDIOPATHIC HYPERSOMNIA
* ZEVRA THERAPEUTICS INC - TOPLINE DATA FROM COMPLETED TRIAL
EXPECTED IN FIRST HALF 2024, WITH POTENTIAL TO INITIATE PHASE 3
TRIAL BY END OF 2024
* ZEVRA THERAPEUTICS - DATA INDICATE SDX IS WELL-TOLERATED
ACROSS
ALL DOSES AND BOTH DOSING REGIMENS STUDIED, LAYING GROUNDWORK
FOR FUTURE PHASE 3 TRIAL
Source text for Eikon: ID:nGNX1pfzZT
Further company coverage: ZVRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zevra Therapeutics
See all newsZevra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales
Zevra Therapeutics Inc expected to post earnings of 11 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
U.S. STOCKS ON THE MOVE-Booz Allen Hamilton, Sensient, Amkor